Clinical Trials

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT04150029 2026-01-13

STIMULUS-AML1

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT06384261 2025-09-10

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Phase 2 Recruiting

120 enrolled

Leukemia, Myeloid, Acute

NCT04023526 2025-08-20

CULMINATE

103 enrolled 19 charts

Leukemia, Myeloid, Acute

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

100 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02494258 2025-05-22

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

5 enrolled

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

54 enrolled 26 charts

Myeloid Malignancies

NCT03931291 2025-03-17

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

33 enrolled 7 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06858618 2025-03-05

FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

47 enrolled

Leukemia, Myeloid, Acute

NCT04905407 2025-02-24

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

66 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT02807558 2024-12-13

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

155 enrolled 24 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02250326 2024-09-19

abound2L+

240 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06532058 2024-08-01

Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Recruiting

53 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02775903 2023-02-28

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

213 enrolled 35 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

120 enrolled 39 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04264806 2022-05-20

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01912274 2021-02-09

Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

50 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT02450877 2019-12-20

A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.

7 enrolled

Leukemia, Myeloid, Acute

NCT02447666 2019-07-11

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

28 enrolled 1 FDA

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Juvenile

NCT01358734 2019-06-25

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

88 enrolled 17 charts

Leukemia, Myeloid, Acute

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

97 enrolled 18 charts

Breast

Breast Neoplasms

NCT00384839 2018-10-25

Vidaza to Restore Hormone Thx Prostate

36 enrolled 10 charts

Genitourinary

Prostatic Neoplasms

NCT02147873 2016-10-20

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

118 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00543582 2015-07-01

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

23 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00666497 2015-05-08

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

6 enrolled